Enatumab for relapsed or resistant warm antibody autoimmune hemolytic anemia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new drug called enatumab that may help people with a type of autoimmune anemia where the body attacks its own red blood cells. If you have not responded to previous treatments or your condition has returned, this trial might offer a new option to improve your hemoglobin levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of warm antibody autoimmune hemolytic anemia (a condition where your immune system attacks your red blood cells).
- You must have tried at least two lines of treatment for your anemia (such as steroids, rituximab, or other immune-suppressing drugs) and it either stopped working or the disease came back.
- Your hemoglobin level (a measure of your red blood cells) must be between 60 and 100 grams per liter.
- Your liver and kidney function must be within acceptable limits, and you must not have active infections (like hepatitis B or C, HIV) or a history of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine for people with autoimmune hemolytic anemia (AIHA) that has not improved with standard treatments. The goal is to see if the drug can help control the disease and improve red blood cell counts.
This study tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can help control the anemia and reduce the need for ongoing treatments.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This study tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia that hasn't improved after other treatments. The goal is to see if this therapy can help control the disease and be safe.
This trial tests a new cell treatment called YTS109 for people with autoimmune hemolytic anemia (AIHA) that has not improved after several standard treatments. The goal is to see if this treatment can help control the disease.
This trial tests a new type of cell therapy (called CAR-T) for people with autoimmune hemolytic anemia or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can control the condition and reduce the need for ongoing immune-suppressing drugs.
Hear when a new Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.